Clinical Study of Aidi Injection Combined with Transcather Hepatic Arterial Chemoembolization in the Treatment of Primary Liver Cancer

Objective To investigate the therapeutic effect of Aidi injection combined with transcather hepatic arterial chemoembolization in treatment for primary liver cancer. Methods Sixty-three cases with primary liver cancer were randomly divided into two groups. The treated group (n=33) received Aidi injection combined with transcather hepatic arterial chemoembolization, and the control group (n=30) were treated with transcather hepatic arterial chemoembolization alone. Results The response rates in the treated group and control group were 60.6% and 53.3% respectively .The remission of symptoms were 72.7% and 33.3% respectively .The improvement of life quantity were 54.5% and 30.3% respectively. In the clinical symptoms and the quality of life, there were significant difference between the two groups, P 0.05. Conclusion The treatment of Aidi injection combined with transcather hepatic arterial chemoembolization was helpful to improve the clinical symptoms and the quality of life for patients with primary liver cancer.